Human embryonic stem cells (hESCs) have an unlimited capacity for self-renewal, and the ability to differentiate into cells derived from all three embryonic germ layers (1). Directed differentiation of hESCs into specific cell types has generated much interest in the field of regenerative medicine (e.g., (2-5)), and methods for determining the in vivo fate of selected or manipulated hESCs are essential to this endeavor. We have adapted a highly efficient teratoma formation assay for this purpose. A small number of specifically selected hESCs is mixed with undifferentiated wild type hESCs and Phaseolus vulgaris lectin to form a cell pellet. This is grafted beneath the kidney capsule in an immunodeficient mouse. As few as 2.5 x 10 5 hESCs are needed to form a 16 cm 3 teratoma within 8-12 weeks. The fate of the originally selected hESCs can then be determined by immunohistochemistry. This method provides a valuable tool for characterizing tissue-specific reagents for cell-based therapy.
6. To help bind the cells together for transplant, add 100μl 1 mg/ml Phaseolus vulgaris lectin (PHA) in DPBS to each tube. 7. Incubate the cell/PHA suspension at room temperature for 5 minutes, then spin for 2 minutes at 8,000 x g. Rotate the tubes 180° within their rotor wells and spin again for 2 minutes at 8,000 x g. 8. Carefully aspirate the supernatant leaving the pellet intact. 9. Dislodge the cell pellets from the tubes by gently pipetting 200μl KSR next to the edge of the pellet until it slowly lifts up. 10 . Once dislodged, immediately transfer the pellets to 0.4μm MILLICELL inserts placed in 3.5 cm diameter wells containing 3 ml KSR, and incubate for 2 hours to overnight at 37°C/5%CO 2 .
III. Renal capsule grafting 1 . Perform all animal procedures in accordance with institutional guidelines using appropriate aseptic technique. 2. Anesthetize SCID beige mice (CB17.Cg-Prkdc scid Lyst bg /Crl), aged 8-12 weeks, using a combination of inhaled 3% isoflurane/0.5%O2 and intraperitoneal tribromoethanol (Avertin; 25 mg/kg freshly prepared). Two cell pellets per mouse will be engrafted using described techniques (10). 3. After placing the mouse on a heating pad to prevent hypothermia, shave the incision area, then disinfect it with chlorhexidine. Make a 2.5 cm incision through the skin just off center but parallel to the spine. 4. Keeping the incision area moist with sterile saline, make a smaller incision through the muscle, just below the ribs and ~1 cm from the spine.
The incision should be just large enough to pull the kidney through, but small enough that the kidney will not slip back into the abdominal cavity without force. 5. Pull the kidney gently through the muscle incision using a glass Pasteur pipette that has been pulled into the shape of a blunt, slightly curved hook. 6. Wet the kidney with sterile DPBS to prevent the capsule from drying out. This may be necessary to repeat throughout the procedure, as the capsule is very fragile. 7. Using Dumont #5 forceps, gently pull the capsule up from the kidney and make a 2 mm incision using Vannas spring scissors. 8. With another glass pipette that has been pulled into a very fine, blunted probe, make a small pocket between the capsule and the kidney. 9. Using a large-orifice pipette tip placed on a disposable transfer pipette, take a single cell pellet from the MILLICELL insert. Make sure to take as little extra media along as possible, as excess media can interfere with the pellet transfer. 10. While holding up the edge of the incision to create the pocket, gently place the pellet next to the opening and push it into the pocket toward one pole of the kidney with the pulled pipette. 11. Repeat the process with a second pellet. Place this under the capsule of the same kidney, but toward the opposite pole. 12. Carefully place the capsule back down onto the pellets. The pellets should stay within the pocket, and no sutures are necessary to close the capsule. 13. Gently push the kidney back into the abdominal cavity and close the muscle wall using 4-0 silk sutures (or smaller) with attached reversecutting needle. The incision should be small enough that only a single suture is necessary. 14. Close the skin with a series of 4-5 interrupted stitches, using the same suture material. 15. Before placing the mouse back in its cage, administer 0.05 mg/kg buprenorphine (11,12) and 5 mg/kg ketoprofen (12,13) as short-term and long-term analgesics, respectively. Controlled substances should only be used in accordance with institutional guidelines. 16. Transfer the animal back to its cage and allow it to recover from anesthesia on a heating pad. This should take about 20-30 minutes. 17. Once the mouse is fully ambulatory, it can be returned to the animal housing facility.
IV. Teratoma harvest, fixation and sectioning
1. At 8-12 weeks post-surgery, there should be a barely palpable teratoma near the kidney. Large, fluid-filled cysts will often develop as well, starting at 6-8 weeks. These may necessitate an earlier harvest if they cause distress to the animal. Since teratomas grow at slower rates than cysts, however, you will want to wait as long as possible to obtain a teratoma of sufficient size for analysis (i.e., at least 8 weeks). 2. Remove the kidney, teratoma, and any surrounding cysts as a block of tissue from the abdominal cavity using the same surgical approach by which the kidney was originally accessed (see Section III, steps 1-4 above). 3. Place the entire block of excised tissue into a tube containing 10% buffered formalin. 4. Allow the teratoma to fix overnight at 4°C. 5. The following day, remove the teratoma from the tube. Dissect away any cysts and as much kidney as possible without damaging the teratoma itself (Figure 3) . Larger teratomas may be cut in half to facilitate dissection and embedding. 6. Process the teratoma using a standard paraffin-fixation technique. Automated units are available (e.g., Shandon Hypercenter): . Teratoma analysis can be used to map the fate of tagged, undifferentiated hESCs. As previously published (9), a mixture of specifically tagged hESCs with untagged hESCs can be used to map the fate of the tagged cells in a teratoma formation assay. As shown here, undifferentiated hESCs expressing the surface marker, CD133, and tagged with enhanced green fluorescent protein (eGFP), were mixed with untagged, undifferentiated hESCs. These were used to form teratomas by renal capsule grafting. Immunohistochemical analysis of hematoxylin and eosin-stained teratoma sections with anti-eGFP antibody demonstrates the neuroectodermal fate of the CD133+ hESCs. Teratomas were processed as in Figure 4 and counterstained with anti-eGFP antibody (brown) to localize derivatives of CD133+GFP+ cells within tissues. CD133+-derived cells (arrows) were observed in tissues arising from embryonic ectoderm, specifically neural epithelium (left) and nascent neural tube-like structures (right). Bar, 100 μm. Images reprinted with permission of author.
Gelatin
• 0.1% Porcine gelatin • 99.9% DPBS • Add gelatin to DPBS, incubate at 37°C for one hour or until all gelatin goes into solution, and filter sterilize (0.22μm) before use.
MEF medium
• • Store at 4°C, but warm to 37°C before adding to cells.
• Add bFGF immediately before use.
Collagenase IV
• Dissolve 1 mg/ml in KSR medium by placing at 37°C for 1-2 hours or until all powder goes into solution.
• Filter sterilize.
Avertin
• 0.25 g 2,2,2-tribromoethanol • 0.25 ml 2-methyl-2-butanol • Incubate at 37°C overnight to form 100% solution.
• Several hours before surgery, dilute to 2.5% working solution using DPBS and incubate at 37°C for at least 1 hour.
• Filter sterilize and aliquot.
• Tribromoethanol is highly light-sensitive, so protect from light at all stages of preparation and use.
• Prepare no more than 12-24 hours before use.
Buprenorphine
• 1 mg/ml stock solution in methanol • Dilute to 0.015 mg/ml working solution using sterile H 2 O.
• Store at -20°C for up to 1 month.
Ketoprofen
• 0.5 mg/ml working solution in DPBS • Add DPBS, incubate overnight at 37°C for 1-2 hours or until all powder goes into solution.
• Filter sterilize and store at 4°C.
Discussion
We have adapted a highly efficient teratoma formation assay for the purpose of mapping the fate of differentiating hESCs in an in vivo environment. A small number of specifically selected hESCs is mixed with undifferentiated wild type hESCs and Phaseolus vulgaris lectin to form a cell pellet. This is grafted beneath the kidney capsule in an immunodeficient mouse. The fate of the originally selected hESCs can then be determined by immunohistochemistry (Figure 5) , as previously reported (9) . This method provides a valuable tool for identifying and generating tissue-specific reagents for cell-based therapy.
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